Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

Dow Jones06-30 06:50

AeroVironment reported a more than twofold increase in fourth-quarter revenue, ahead of Wall Street estimates. Shares were up 20% to $166.17 after the bell on Monday.

Concentrix cut its full-year outlook and guided for third-quarter results below analyst expectations. The stock fell 23% to $19.55 in after-hours trading.

Gain Therapeutics got approval from the Food and Drug Administration to launch a Phase 2 study of a treatment for Parkinson's disease. The stock rose 19% to $2.36.

Praxis Precision Medicines said the FDA extended its review of the company's epilepsy treatment application by three months. Shares were down 3.1% to $339.90.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

June 29, 2026 18:50 ET (22:50 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647130023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 06:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647130023","market":"other","top_or_hot":-1,"title":"Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AeroVironment reported a more than twofold increase in fourth-quarter revenue, ahead of Wall Street estimates. Shares were up 20% to $166.17 after the bell on Monday. \n</p>\n<p>\n  Concentrix cut its full-year outlook and guided for third-quarter results below analyst expectations. The stock fell 23% to $19.55 in after-hours trading. \n</p>\n<p>\n  Gain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> got approval from the Food and Drug Administration to launch a Phase 2 study of a treatment for Parkinson's disease. The stock rose 19% to $2.36. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> said the FDA extended its review of the company's epilepsy treatment application by three months. Shares were down 3.1% to $339.90. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 18:50 ET (22:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 06:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AeroVironment reported a more than twofold increase in fourth-quarter revenue, ahead of Wall Street estimates. Shares were up 20% to $166.17 after the bell on Monday. \n</p>\n<p>\n  Concentrix cut its full-year outlook and guided for third-quarter results below analyst expectations. The stock fell 23% to $19.55 in after-hours trading. \n</p>\n<p>\n  Gain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> got approval from the Food and Drug Administration to launch a Phase 2 study of a treatment for Parkinson's disease. The stock rose 19% to $2.36. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> said the FDA extended its review of the company's epilepsy treatment application by three months. Shares were down 3.1% to $339.90. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 18:50 ET (22:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GANX","symbol_name":"Gain Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647130023","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647130023","pubTimestamp":1782773400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AeroVironment reported a more than twofold increase in fourth-quarter revenue, ahead of Wall Street estimates. Shares were up 20% to $166.17 after the bell on Monday.Concentrix cut its full-year outlook and guided for third-quarter results below analyst expectations. The stock fell 23% to $19.55 in after-hours trading.Gain Therapeutics got approval from the Food and Drug Administration to launch a Phase 2 study of a treatment for Parkinson's disease. The stock rose 19% to $2.36.Praxis Precision Medicines said the FDA extended its review of the company's epilepsy treatment application by three months. Shares were down 3.1% to $339.90.Write to Elias Schisgall at elias.schisgall@wsj.com Dow Jones NewswiresJune 29, 2026 18:50 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GANX":"Gain Therapeutics, Inc.","PRAX":"Praxis Precision Medicines, Inc.","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4106":"数据处理与外包服务","BK4603":"无人机概念股","BK4226":"数据处理及外包服务","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","AVXX":"2倍做多AVAV ETF-Defiance","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4187":"航天航空与国防","AVAV":"AeroVironment公司","CNXC":"Concentrix Corp","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4139":"生物科技","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"值得关注的股票：Aerovironment、Concentrix、Gain Therapeutics、Praxis Precision Medicines","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXX":0.6,"PRAX":1.5,"AVAV":0.9,"CNXC":0.9,"GANX":1.5},"content_text":"AeroVironment reported a more than twofold increase in fourth-quarter revenue, ahead of Wall Street estimates. Shares were up 20% to $166.17 after the bell on Monday. \n\n\n  Concentrix cut its full-year outlook and guided for third-quarter results below analyst expectations. The stock fell 23% to $19.55 in after-hours trading. \n\n\n  Gain Therapeutics got approval from the Food and Drug Administration to launch a Phase 2 study of a treatment for Parkinson's disease. The stock rose 19% to $2.36. \n\n\nPraxis Precision Medicines said the FDA extended its review of the company's epilepsy treatment application by three months. Shares were down 3.1% to $339.90. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 18:50 ET (22:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647130023","isCrawlerRequest":true}